EU regulators reviewing J&J’s COVID vaccine after blood clots

Johnson & Johnson is working with European Union regulators to assess data on the rare clots, and ‘at present, no clear causal relationship has been established’ with the vaccine, the company said in an emailed statement.

The European Union’s drug regulator has started a review to assess blood clots in people who received Johnson & Johnson’s Covid-19 vaccine. Four serious cases of unusual clots accompanied by low blood platelets, one of which was fatal, have emerged after immunization with the J&J shot, the European Medicines Agency said Friday. The regulator is now scrutinizing potential safety issues for two Covid vaccines, after AstraZeneca Plc’s shot was possibly linked to a rare blood-clotting disorder. J&J is working with regulators to assess data on the rare clots, and “at present, no clear causal relationship has been established” with the vaccine, the company said in an e-mailed statement. The shares traded as much as 1.6% lower.